Group 1 - The top three companies with the highest short positions are WuXi AppTec (02359), CATL (03750), and COSCO Shipping Holdings (01919), with short ratios of 23.99%, 17.39%, and 14.14% respectively [1][2] - The companies with the largest increase in short positions are Giant Biogene (02367), WuXi AppTec (02359), and Henderson Land Development (00012), with increases of 2.05%, 1.43%, and 1.41% respectively [1][2] - The companies with the largest decrease in short positions are SF Holding (06936), Far East Horizon (03360), and Jiumaojiu International Holdings (09922), with decreases of -1.94%, -1.22%, and -1.18% respectively [1][3] Group 2 - The top ten companies with the highest short ratios include Ganfeng Lithium (01772) at 13.09%, Xiexin Technology (03800) at 12.57%, and Shandong Gold (01787) at 12.35% [2] - The companies with the largest increase in short ratios also include Fuyou Glass (06865) at 12.07% and Tigermed (03347) at 9.81% [2] - The companies with the largest decrease in short ratios include Vanke Enterprise (02202) at 11.38% and Green Leaf Pharmaceutical (02186) at 11.96% [3][4]

Core Viewpoint - The article discusses the recent performance and challenges faced by Kanglong Chemical (康龙化成), highlighting a recent incident among employees and the company's financial forecasts for 2025, indicating a mixed outlook with revenue growth but declining net profits [3][6]. Financial Performance - Kanglong Chemical expects total revenue for the first half of 2025 to be between 6.3 billion to 6.5 billion, representing a year-on-year growth of 13% to 16%. However, net profit is projected to decline by 36% to 39%, primarily due to a significant one-time gain from equity disposal in the previous year [6]. - The company reported a total revenue of 12.28 billion in 2024, with a growth rate of 6.39% compared to 2023. The revenue breakdown shows that laboratory services accounted for 57.40% of total revenue, while CMC services contributed 24.35% [8][12]. Industry Context - Kanglong Chemical is a prominent Contract Research Organization (CRO) in China, assisting clients in accelerating drug innovation through various services, including laboratory services and clinical research [7]. - The CRO sector was previously highly sought after in the capital market, with Kanglong Chemical's stock price increasing over 26 times within three years post-IPO, reaching a market capitalization close to 200 billion [9]. - The company has faced challenges since the US-China trade tensions, leading to a significant slowdown in growth, with 2024 revenue growth dropping to single digits [12]. Operational Strategy - To mitigate market challenges, Kanglong Chemical has established 21 R&D centers and production bases across China, the UK, and the US, with North America being the primary revenue source, contributing over 60% [17]. - The company reported a 16% year-on-year revenue growth in Q1 2025, indicating a positive trend despite previous high growth rates [22]. Shareholder Activity - Since its IPO, major shareholders, including the controlling shareholder and executives, have continuously reduced their holdings, with total cashing out amounting to 21.45 billion in the A-share market [25][26].

Group 1 - The A-share CRO (Contract Research Organization) sector experienced a significant rally in the afternoon, with notable stocks such as Chengdu Xian Dao hitting the daily limit up [1] - MediXy and Hite Bio both surged over 14%, indicating strong investor interest and market momentum [1] - Other companies in the sector, including Zhaoyan New Drug, Yinuosi, Sunshine Nuohe, Kanglong Huacheng, and Puris, also saw positive gains, reflecting a broader trend in the CRO market [1]

Group 1 - The Hang Seng Index rose by 0.28%, gaining 68 points to close at 24,658 points, while the Hang Seng Tech Index increased by 0.61% [1] - The Hong Kong stock market saw a trading volume of HKD 157.9 billion in the morning session [1] - The National Healthcare Security Administration of China added innovative commercial insurance drugs to the list for 2025, supporting new drugs with high clinical value but payment bottlenecks, leading to a rise in the Hang Seng Biotechnology Index [1] Group 2 - Livzon Pharmaceutical (01513) surged by 12.69% as the Phase II clinical trial for its cardiovascular innovative drug H001 capsule completed patient enrollment [2] - InnoCare Pharma (02577) increased by 6.41%, planning to significantly enhance its 8-inch gallium nitride wafer production capacity over the next five years [2] - China Heartland Fertilizer (01866) rose by 3.83% following reports of a meeting held by relevant authorities to ensure the supply and stabilize prices of potash fertilizer [2] Group 3 - Chongqing Machinery and Electric (02722) saw a significant increase of over 17% due to catalysts in the domestic AIDC market, with Chongqing Cummins being a supplier for engines [2] Group 4 - Jifang Zhitu Holdings (09636) rose by 10.18% after announcing a proposed share placement to raise approximately HKD 746 million for developing on-chain financial resources [3] Group 5 - Smoore International (06969) fell by 3.55%, expecting a year-on-year decline of approximately 21% to 35% in half-year profits [4] - Kanglong Chemical (03759) issued a profit warning, dropping by 5.24%, with an expected year-on-year decline of 36% to 39% in net profit attributable to shareholders for the first half [5]

Group 1 - HSK47388, a self-developed oral drug by the company, has received FDA approval to initiate clinical trials for the treatment of autoimmune diseases, showing significant dose-dependent anti-inflammatory effects and good safety profile in preclinical studies [1] - The drug's large safety window provides a favorable foundation for subsequent clinical research, potentially filling existing treatment gaps for autoimmune disease patients [1] Group 2 - Kanglong Chemical's net profit for the first half of 2025 is expected to decline by 36% to 39%, reflecting short-term pressures in the CRO industry due to global biopharmaceutical investment slowdown, order delays, and rising costs [2] - Dezheng Health anticipates a net loss of approximately 25 million to 50 million yuan for the first half of the year, a significant decline from a profit of 10.15 million yuan in the same period last year, attributed to the impact of centralized procurement and high sales expenses [3] - China National Pharmaceutical's acquisition of 95.09% of Lixin Pharmaceutical is expected to enhance its innovative drug revenue share, reflecting a trend of domestic pharmaceutical companies strengthening their competitive edge through mergers and acquisitions [4] - Baicheng Pharmaceutical forecasts a net profit decline of over 95% for the first half of 2025, with government subsidies contributing significantly to its profits, indicating challenges in its core business capabilities during its strategic transformation [5]

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown positive growth in recent months and has a significant allocation in leading healthcare companies [1][3]. - As of July 15, 2025, the latest net value of the fund is 1.7462 yuan, reflecting a growth of 1.28%. The fund's one-month return is 2.18%, six-month return is 18.43%, and year-to-date return is 14.30% [1]. - The fund's top ten stock holdings account for a total of 55.30%, with significant investments in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Mindray Medical (5.21%) [1]. Group 2 - The China Europe Medical Health Mixed Fund C was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan. The fund is managed by Guo Lan and Zhao Lei [1]. - Guo Lan, the fund manager, has a background in biomedical engineering and has held various positions in research and fund management since joining China Europe Fund Management in 2014 [2]. - Zhao Lei, also a fund manager, has experience in the pharmaceutical and biotechnology sectors, having worked as a researcher and analyst before joining China Europe Fund Management in 2021 [2].

康龙化成（北京）新药技术股份有限公司 2025年半年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 以下为本公司的 2025 年半年度业绩预告。本业绩预告所载之财务数据未经 审计，除经调整的非《国际财务报告准则》下归属于上市公司股东的净利润或另 有注释外，本业绩预告所载之财务数据根据中国企业会计准则编制。 一、本期业绩预计情况 1、业绩预告期间 证券代码：300759 证券简称：康龙化成 公告编号：2025-038 2025 年 1 月 1 日至 2025 年 6 月 30 日 2、业绩预告情况 预计营业收入、归属于上市公司股东的扣除非经常性损益后的净利润以及经 调整的非《国际财务报告准则》下归属于上市公司股东的净利润同向上升，预计 归属于上市公司股东的净利润同向下降。 | 项 目 | 本报告期 | 上年同期 | | --- | --- | --- | | 营业收入 | 营收：633,304.36 万元–650,117.75 万元 | 营收：560,446.34 万元 | | | 比上年同期增长：13%–16% | | | 归属于上市公司股东 | ...

康龙化成（300759）公告，信息披露义务人信中康成及其一致行动人信中龙成合计减持公司股份5521.3 万股，占公司总股本的3.36%。此次减持包括集中竞价交易和大宗交易两种方式，减持期间为2023年1 月10日至2025年7月9日。此次减持是由于信息披露义务人自身资金需求以及公司历次激励计划归属的限 制性股票上市、回购注销股份、权益分派等原因导致股份比例被动变动。未来12个月内，信息披露义务 人将继续减持股份并计划在未来12个月内无增持计划。 ...

证券代码：300759 证券简称：康龙化成 公告编号：2025-037 康龙化成（北京）新药技术股份有限公司 关于持股 5%以上股东权益变动 触及 1%和 5%整数倍的提示性公告 公司持股 5%以上股东深圳市信中康成投资合伙企业（有限合伙）及其一致行 动人深圳市信中龙成投资合伙企业（有限合伙）保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）于近日收到 公司持股 5%以上股东深圳市信中康成投资合伙企业（有限合伙）（以下简称"信 中康成"）及其一致行动人深圳市信中龙成投资合伙企业（有限合伙）（以下简称 "信中龙成"）出具的《股份减持进展告知函》，获悉信中康成和信中龙成因减持、 公司总股本变动等原因导致权益变动触及 1%和 5%的整数倍。现将有关情况公 告如下： 1.基本情况 信息披露义务人 （一） 深圳市信中康成投资合伙企业（有限合伙） 住所 深圳市前海深港合作区南山街道兴海大道 3046 号香江金 融大厦 1314-B8 信息披露义务人 （二） 深圳市信 ...

康龙化成（北京）新药技术股份有限公司 简式权益变动报告书 上市公司名称：康龙化成（北京）新药技术股份有限公司 股票上市地点：深圳证券交易所（A股）、香港联合交易所（H股） 股票简称：康龙化成（A股、H股） 股票代码：300759.SZ/03759.HK 信息披露义务人（一）：深圳市信中康成投资合伙企业（有限合伙） 住所：深圳市前海深港合作区南山街道兴海大道3046号香江金融大厦1314-B8 通讯地址：北京市朝阳区京城大厦16层 信息披露义务人（二）：深圳市信中龙成投资合伙企业（有限合伙） 住所：深圳市前海深港合作区前湾一路1号A栋201室（入驻深圳市前海商务秘 书有限公司） 通讯地址：北京市朝阳区京城大厦16层 签署日期：2025年7月9日 2 1 信息披露义务人声明 一、本报告书依据《中华人民共和国证券法》《上市公司收购管理办法》 《公开发行证券的公司信息披露内容与格式准则第15号—权益变动报告书》 （以下简称"《准则15号》"）及相关的法律、法规和规范性文件编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不 违反信息披露义务人合伙协议或内部规则中的任何条款，或与之相冲突。 三、依据 ...